Gene Activity List


Gene Activity List

Gene Compound Assay Inh Ic50 Ki View
solute carrier family 6 (neurotransmitter transporter, dopamine), member 3 DANAZOL Dopamine Transporter 89% 6.842uM 5.436uM View
arachidonate 15-lipoxygenase, second type BETA-ESTRADIOL Lipoxygenase 15-LO 89% 11.295uM NoneNone View
arachidonate 15-lipoxygenase BETA-ESTRADIOL Lipoxygenase 15-LO 89% 11.295uM NoneNone View
arachidonate 15-lipoxygenase BETA-ESTRADIOL Lipoxygenase 15-LO 89% 11.295uM NoneNone View
nuclear receptor subfamily 3, group C, member 1 ETHINYLESTRADIOL Glucocorticoid 89% 1.71uM .777uM View
solute carrier family 6 (neurotransmitter transporter, dopamine), member 3 4-OCTYLPHENOL Dopamine Transporter 89% 8.491uM 6.746uM View
prostaglandin-endoperoxide synthase 2 PHENOTHIAZINE Cyclooxygenase COX-2 89% .532uM NoneNone View
prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) PHENOTHIAZINE Cyclooxygenase COX-2 89% .532uM NoneNone View
calcium channel, voltage-dependent, gamma subunit 4 TIRILAZAD Calcium Channel Type L, Benzothiazepine 89% 2.694uM 2.395uM View
potassium voltage-gated channel, subfamily H, member 8 MITOXANTRONE Potassium Channel HERG 89% 3.5849uM 2.937uM View
potassium voltage-gated channel, subfamily H (eag-related), member 6 MITOXANTRONE Potassium Channel HERG 89% 3.5849uM 2.937uM View
potassium voltage-gated channel, subfamily H (eag-related), member 7 MITOXANTRONE Potassium Channel HERG 89% 3.5849uM 2.937uM View
potassium voltage-gated channel, subfamily H (eag-related), member 2 MITOXANTRONE Potassium Channel HERG 89% 3.5849uM 2.937uM View
potassium voltage-gated channel, subfamily H (eag-related), member 5 MITOXANTRONE Potassium Channel HERG 89% 3.5849uM 2.937uM View
potassium voltage-gated channel, subfamily H (eag-related), member 3 MITOXANTRONE Potassium Channel HERG 89% 3.5849uM 2.937uM View
potassium voltage-gated channel, subfamily H (eag-related), member 4 MITOXANTRONE Potassium Channel HERG 89% 3.5849uM 2.937uM View
potassium voltage-gated channel, subfamily H (eag-related), member 1 MITOXANTRONE Potassium Channel HERG 89% 3.5849uM 2.937uM View
potassium voltage-gated channel, subfamily H (eag-related), member 1 MITOXANTRONE Potassium Channel HERG 89% 3.5849uM 2.937uM View
Cytochrom P450-1A2 monooxygenase BW-723C86 CYP450-1A2 Inhibition 89% .8738uM NoneNone View
calcium channel, voltage-dependent, gamma subunit 8 PERHEXILINE Calcium Channel Type L, Benzothiazepine 89% 1.0569uM .9394uM View
calcium channel, voltage-dependent, gamma subunit 7 PERHEXILINE Calcium Channel Type L, Benzothiazepine 89% 1.0569uM .9394uM View
calcium channel, voltage-dependent, gamma subunit 6 PERHEXILINE Calcium Channel Type L, Benzothiazepine 89% 1.0569uM .9394uM View
calcium channel, voltage-dependent, gamma subunit 5 PERHEXILINE Calcium Channel Type L, Benzothiazepine 89% 1.0569uM .9394uM View
thromboxane A synthase 1 GRAMICIDIN Thromboxane Synthetase 88% .774uM NoneNone View
thromboxane A synthase 1 (platelet, cytochrome P450, family 5, subfamily A) GRAMICIDIN Thromboxane Synthetase 88% .774uM NoneNone View
adrenergic receptor, alpha 2a METHAPYRILENE Adrenergic alpha2A 88% 1.165uM .437uM View
Sigma-2 Receptor BROMHEXINE Sigma2 88% .059uM .036uM View
arachidonate 15-lipoxygenase, second type FERULIC ACID Lipoxygenase 15-LO 88% 3.975uM NoneNone View
arachidonate 15-lipoxygenase FERULIC ACID Lipoxygenase 15-LO 88% 3.975uM NoneNone View
arachidonate 15-lipoxygenase FERULIC ACID Lipoxygenase 15-LO 88% 3.975uM NoneNone View
histamine receptor H 2 BENZTROPINE Histamine H2 88% 1.206uM 1.185uM View
sodium channel, voltage-gated, type VII, alpha BENZTROPINE Sodium Channel, Site 2 88% 1.68uM 1.533uM View
amiloride-sensitive cation channel 5, intestinal BENZTROPINE Sodium Channel, Site 2 88% 1.68uM 1.533uM View
sodium channel, voltage-gated, type III, beta BENZTROPINE Sodium Channel, Site 2 88% 1.68uM 1.533uM View
sodium channel, voltage-gated, type VIII, alpha polypeptide BENZTROPINE Sodium Channel, Site 2 88% 1.68uM 1.533uM View
sodium channel, voltage-gated, type XI, alpha BENZTROPINE Sodium Channel, Site 2 88% 1.68uM 1.533uM View
sodium channel, voltage-gated, type I, beta BENZTROPINE Sodium Channel, Site 2 88% 1.68uM 1.533uM View
sodium channel, voltage-gated, type 10, alpha polypeptide BENZTROPINE Sodium Channel, Site 2 88% 1.68uM 1.533uM View
sodium channel, voltage-gated, type IV, alpha polypeptide BENZTROPINE Sodium Channel, Site 2 88% 1.68uM 1.533uM View
sodium channel, voltage-gated, type V, alpha polypeptide BENZTROPINE Sodium Channel, Site 2 88% 1.68uM 1.533uM View
sodium channel, voltage-gated, type II, beta BENZTROPINE Sodium Channel, Site 2 88% 1.68uM 1.533uM View
sodium channel, nonvoltage-gated 1 alpha BENZTROPINE Sodium Channel, Site 2 88% 1.68uM 1.533uM View
sodium channel, nonvoltage-gated 1 gamma BENZTROPINE Sodium Channel, Site 2 88% 1.68uM 1.533uM View
sodium channel, nonvoltage-gated 1 beta BENZTROPINE Sodium Channel, Site 2 88% 1.68uM 1.533uM View
sodium channel, voltage-gated, type 2, alpha 1 polypeptide BENZTROPINE Sodium Channel, Site 2 88% 1.68uM 1.533uM View
sodium channel, voltage-gated, type XI, alpha BENZTROPINE Sodium Channel, Site 2 88% 1.68uM 1.533uM View
sodium channel, nonvoltage-gated 1, gamma BENZTROPINE Sodium Channel, Site 2 88% 1.68uM 1.533uM View
sodium channel, nonvoltage-gated 1, delta BENZTROPINE Sodium Channel, Site 2 88% 1.68uM 1.533uM View
sodium channel, nonvoltage-gated 1, beta (Liddle syndrome) BENZTROPINE Sodium Channel, Site 2 88% 1.68uM 1.533uM View
sodium channel, nonvoltage-gated 1 alpha BENZTROPINE Sodium Channel, Site 2 88% 1.68uM 1.533uM View
sodium channel, voltage-gated, type X, alpha BENZTROPINE Sodium Channel, Site 2 88% 1.68uM 1.533uM View
sodium channel, voltage-gated, type IX, alpha BENZTROPINE Sodium Channel, Site 2 88% 1.68uM 1.533uM View
sodium channel, voltage gated, type VIII, alpha BENZTROPINE Sodium Channel, Site 2 88% 1.68uM 1.533uM View
sodium channel, voltage-gated, type VII, alpha BENZTROPINE Sodium Channel, Site 2 88% 1.68uM 1.533uM View
sodium channel, voltage-gated, type V, alpha (long QT syndrome 3) BENZTROPINE Sodium Channel, Site 2 88% 1.68uM 1.533uM View
sodium channel, voltage-gated, type IV, beta BENZTROPINE Sodium Channel, Site 2 88% 1.68uM 1.533uM View
sodium channel, voltage-gated, type IV, alpha BENZTROPINE Sodium Channel, Site 2 88% 1.68uM 1.533uM View
sodium channel, voltage-gated, type III, alpha BENZTROPINE Sodium Channel, Site 2 88% 1.68uM 1.533uM View
sodium channel, voltage-gated, type II, beta BENZTROPINE Sodium Channel, Site 2 88% 1.68uM 1.533uM View
sodium channel, voltage-gated, type II, alpha 2 BENZTROPINE Sodium Channel, Site 2 88% 1.68uM 1.533uM View
sodium channel, voltage-gated, type I, beta BENZTROPINE Sodium Channel, Site 2 88% 1.68uM 1.533uM View
sodium channel, voltage-gated, type I, alpha BENZTROPINE Sodium Channel, Site 2 88% 1.68uM 1.533uM View
sodium channel, voltage-gated, type IV, beta BENZTROPINE Sodium Channel, Site 2 88% 1.68uM 1.533uM View
sodium channel associated protein 1 BENZTROPINE Sodium Channel, Site 2 88% 1.68uM 1.533uM View
sodium channel associated protein 2 BENZTROPINE Sodium Channel, Site 2 88% 1.68uM 1.533uM View
sodium channel, voltage-gated, type III, beta BENZTROPINE Sodium Channel, Site 2 88% 1.68uM 1.533uM View
sodium channel, voltage-gated, type I, alpha BENZTROPINE Sodium Channel, Site 2 88% 1.68uM 1.533uM View
dopamine receptor D4 HALOPERIDOL Dopamine D4.2 87% .563uM .198uM View
adrenergic receptor, alpha 2b HALOPERIDOL Adrenergic alpha2B 87% 1.354uM .618uM View
dopamine receptor D1A GENTIAN VIOLET Dopamine D1 87% 3.102uM 1.551uM View
cholinergic receptor, muscarinic 4 MIANSERIN Muscarinic M4 87% 2.066uM .288uM View
histamine receptor H 2 MIANSERIN Histamine H2 87% 1.008uM .992uM View
Cytochrom P450-2D6 monooxygenase LYSERGOL CYP450-2D6 Inhibition 87% 1uM NoneNone View
dopamine receptor 2 METHYSERGIDE Dopamine D2L 87% .807uM .269uM View
mitogen activated protein kinase 14 1-(2-METHOXYBENZOYL)-4-(PHENYLMETHYL)-PIPERIDINE Protein Serine/Threonine Kinase, p38alpha 87% .746uM NoneNone View
mitogen-activated protein kinase 14 1-(2-METHOXYBENZOYL)-4-(PHENYLMETHYL)-PIPERIDINE Protein Serine/Threonine Kinase, p38alpha 87% .746uM NoneNone View
prostaglandin-endoperoxide synthase 2 ETODOLAC Cyclooxygenase COX-2 87% .561uM NoneNone View
prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) ETODOLAC Cyclooxygenase COX-2 87% .561uM NoneNone View
5-hydroxytryptamine (serotonin) receptor 2B LORATADINE Serotonin 5-HT2B 86% .245uM .156uM View
mitogen activated protein kinase 14 1-(2-FLUOROBENZOYL)-4-(PHENYLMETHYL)-PIPERIDINE Protein Serine/Threonine Kinase, p38alpha 86% .537uM NoneNone View
mitogen-activated protein kinase 14 1-(2-FLUOROBENZOYL)-4-(PHENYLMETHYL)-PIPERIDINE Protein Serine/Threonine Kinase, p38alpha 86% .537uM NoneNone View
A3 adenosine receptor 1-NAPHTHYL ISOTHIOCYANATE Adenosine A3 86% 6.1uM 3.448uM View
acetylcholinesterase (YT blood group) IRINOTECAN Acetylcholinesterase 86% 1.827uM NoneNone View
collagen-like tail subunit (single strand of homotrimer) of asymmetric acetylcholinesterase IRINOTECAN Acetylcholinesterase 86% 1.827uM NoneNone View
acetylcholinesterase IRINOTECAN Acetylcholinesterase 86% 1.827uM NoneNone View
dopamine receptor D1A KETOTIFEN Dopamine D1 86% .872uM .436uM View
opioid receptor, kappa 1 SAQUINAVIR Opiate kappa 86% 6.951uM 2.78uM View
Cytochrome P450, subfamily IIC (mephenytoin 4-hydroxylase) RITONAVIR CYP450-2C9 Inhibition 86% .016uM NoneNone View
cytochrome P450, family 2, subfamily C, polypeptide 9 RITONAVIR CYP450-2C9 Inhibition 86% .016uM NoneNone View
5-hydroxytryptamine (serotonin) receptor 3a OLANZAPINE Serotonin 5-HT3 86% 1.316uM .296uM View
5-hydroxytryptamine (serotonin) receptor 3b OLANZAPINE Serotonin 5-HT3 86% 1.316uM .296uM View
sodium channel, voltage-gated, type IV, beta ORPHENADRINE Sodium Channel, Site 2 86% 2.492uM 2.274uM View
sodium channel associated protein 1 ORPHENADRINE Sodium Channel, Site 2 86% 2.492uM 2.274uM View
sodium channel associated protein 2 ORPHENADRINE Sodium Channel, Site 2 86% 2.492uM 2.274uM View
sodium channel, voltage-gated, type III, beta ORPHENADRINE Sodium Channel, Site 2 86% 2.492uM 2.274uM View
sodium channel, voltage-gated, type I, alpha ORPHENADRINE Sodium Channel, Site 2 86% 2.492uM 2.274uM View
sodium channel, voltage-gated, type IX, alpha ORPHENADRINE Sodium Channel, Site 2 86% 2.492uM 2.274uM View
sodium channel, voltage-gated, type VII, alpha ORPHENADRINE Sodium Channel, Site 2 86% 2.492uM 2.274uM View
amiloride-sensitive cation channel 5, intestinal ORPHENADRINE Sodium Channel, Site 2 86% 2.492uM 2.274uM View
sodium channel, voltage-gated, type III, beta ORPHENADRINE Sodium Channel, Site 2 86% 2.492uM 2.274uM View
sodium channel, voltage-gated, type VIII, alpha polypeptide ORPHENADRINE Sodium Channel, Site 2 86% 2.492uM 2.274uM View
sodium channel, voltage-gated, type XI, alpha ORPHENADRINE Sodium Channel, Site 2 86% 2.492uM 2.274uM View
sodium channel, voltage-gated, type I, beta ORPHENADRINE Sodium Channel, Site 2 86% 2.492uM 2.274uM View
sodium channel, voltage-gated, type 10, alpha polypeptide ORPHENADRINE Sodium Channel, Site 2 86% 2.492uM 2.274uM View
sodium channel, voltage-gated, type IV, alpha polypeptide ORPHENADRINE Sodium Channel, Site 2 86% 2.492uM 2.274uM View
sodium channel, voltage-gated, type V, alpha polypeptide ORPHENADRINE Sodium Channel, Site 2 86% 2.492uM 2.274uM View
sodium channel, voltage-gated, type II, beta ORPHENADRINE Sodium Channel, Site 2 86% 2.492uM 2.274uM View
sodium channel, nonvoltage-gated 1 alpha ORPHENADRINE Sodium Channel, Site 2 86% 2.492uM 2.274uM View
sodium channel, nonvoltage-gated 1 gamma ORPHENADRINE Sodium Channel, Site 2 86% 2.492uM 2.274uM View
sodium channel, nonvoltage-gated 1 beta ORPHENADRINE Sodium Channel, Site 2 86% 2.492uM 2.274uM View
sodium channel, voltage-gated, type 2, alpha 1 polypeptide ORPHENADRINE Sodium Channel, Site 2 86% 2.492uM 2.274uM View
sodium channel, voltage-gated, type XI, alpha ORPHENADRINE Sodium Channel, Site 2 86% 2.492uM 2.274uM View
sodium channel, nonvoltage-gated 1, gamma ORPHENADRINE Sodium Channel, Site 2 86% 2.492uM 2.274uM View
sodium channel, nonvoltage-gated 1, delta ORPHENADRINE Sodium Channel, Site 2 86% 2.492uM 2.274uM View
sodium channel, nonvoltage-gated 1, beta (Liddle syndrome) ORPHENADRINE Sodium Channel, Site 2 86% 2.492uM 2.274uM View
sodium channel, nonvoltage-gated 1 alpha ORPHENADRINE Sodium Channel, Site 2 86% 2.492uM 2.274uM View
sodium channel, voltage-gated, type X, alpha ORPHENADRINE Sodium Channel, Site 2 86% 2.492uM 2.274uM View
sodium channel, voltage-gated, type IX, alpha ORPHENADRINE Sodium Channel, Site 2 86% 2.492uM 2.274uM View
sodium channel, voltage gated, type VIII, alpha ORPHENADRINE Sodium Channel, Site 2 86% 2.492uM 2.274uM View
sodium channel, voltage-gated, type VII, alpha ORPHENADRINE Sodium Channel, Site 2 86% 2.492uM 2.274uM View
sodium channel, voltage-gated, type V, alpha (long QT syndrome 3) ORPHENADRINE Sodium Channel, Site 2 86% 2.492uM 2.274uM View
sodium channel, voltage-gated, type IV, beta ORPHENADRINE Sodium Channel, Site 2 86% 2.492uM 2.274uM View
sodium channel, voltage-gated, type IV, alpha ORPHENADRINE Sodium Channel, Site 2 86% 2.492uM 2.274uM View
sodium channel, voltage-gated, type III, alpha ORPHENADRINE Sodium Channel, Site 2 86% 2.492uM 2.274uM View
sodium channel, voltage-gated, type II, beta ORPHENADRINE Sodium Channel, Site 2 86% 2.492uM 2.274uM View
sodium channel, voltage-gated, type II, alpha 2 ORPHENADRINE Sodium Channel, Site 2 86% 2.492uM 2.274uM View
sodium channel, voltage-gated, type I, beta ORPHENADRINE Sodium Channel, Site 2 86% 2.492uM 2.274uM View
sodium channel, voltage-gated, type I, alpha ORPHENADRINE Sodium Channel, Site 2 86% 2.492uM 2.274uM View
Cytochrom P450-2D6 monooxygenase BUPIVACAINE HYDROCHLORIDE CYP450-2D6 Inhibition 86% .4uM NoneNone View
calcium channel, voltage-dependent, beta 1 subunit U-78517F Calcium Channel Type L, Dihydropyridine 86% 1.659uM 1.066uM View
calcium channel, voltage-dependent, beta 2 subunit TAMOXIFEN Calcium Channel Type L, Dihydropyridine 85% 8.585uM 5.519uM View
Cytochrom P450-1A2 monooxygenase NIFEDIPINE CYP450-1A2 Inhibition 85% .3uM NoneNone View
adrenergic receptor, alpha 2a ERGONOVINE Adrenergic alpha2A 85% 1.68uM .63uM View
dopamine receptor 2 ERGONOVINE Dopamine D2L 85% .552uM .184uM View
calcium channel, voltage-dependent, gamma subunit 8 CISAPRIDE Calcium Channel Type L, Benzothiazepine 85% .802uM .713uM View
calcium channel, voltage-dependent, gamma subunit 7 CISAPRIDE Calcium Channel Type L, Benzothiazepine 85% .802uM .713uM View
calcium channel, voltage-dependent, gamma subunit 6 CISAPRIDE Calcium Channel Type L, Benzothiazepine 85% .802uM .713uM View
calcium channel, voltage-dependent, gamma subunit 5 CISAPRIDE Calcium Channel Type L, Benzothiazepine 85% .802uM .713uM View
calcium channel, voltage-dependent, gamma subunit 4 CISAPRIDE Calcium Channel Type L, Benzothiazepine 85% .802uM .713uM View
calcium channel, voltage-dependent, gamma subunit 3 CISAPRIDE Calcium Channel Type L, Benzothiazepine 85% .802uM .713uM View
calcium channel, voltage-dependent, gamma subunit 2 CISAPRIDE Calcium Channel Type L, Benzothiazepine 85% .802uM .713uM View
calcium channel, voltage-dependent, gamma subunit 1 CISAPRIDE Calcium Channel Type L, Benzothiazepine 85% .802uM .713uM View
calcium channel, voltage-dependent, beta 4 subunit CISAPRIDE Calcium Channel Type L, Benzothiazepine 85% .802uM .713uM View
calcium channel, voltage-dependent, beta 3 subunit CISAPRIDE Calcium Channel Type L, Benzothiazepine 85% .802uM .713uM View
calcium channel, voltage-dependent, beta 2 subunit CISAPRIDE Calcium Channel Type L, Benzothiazepine 85% .802uM .713uM View
calcium channel, voltage-dependent, L type, alpha 1S subunit CISAPRIDE Calcium Channel Type L, Benzothiazepine 85% .802uM .713uM View
calcium channel, voltage-dependent, alpha 1F subunit CISAPRIDE Calcium Channel Type L, Benzothiazepine 85% .802uM .713uM View
calcium channel, voltage-dependent, L type, alpha 1D subunit CISAPRIDE Calcium Channel Type L, Benzothiazepine 85% .802uM .713uM View
calcium channel, voltage-dependent, L type, alpha 1C subunit CISAPRIDE Calcium Channel Type L, Benzothiazepine 85% .802uM .713uM View
calcium channel, voltage-dependent, P/Q type, alpha 1A subunit CISAPRIDE Calcium Channel Type L, Benzothiazepine 85% .802uM .713uM View
calcium channel, voltage-dependent, beta 1 subunit CISAPRIDE Calcium Channel Type L, Benzothiazepine 85% .802uM .713uM View
calcium channel, voltage-dependent, L type, alpha 1E subunit CISAPRIDE Calcium Channel Type L, Benzothiazepine 85% .802uM .713uM View
calcium channel, voltage-dependent, N type, alpha 1B subunit CISAPRIDE Calcium Channel Type L, Benzothiazepine 85% .802uM .713uM View
calcium channel, voltage-dependent, alpha2/delta subunit 1 CISAPRIDE Calcium Channel Type L, Benzothiazepine 85% .802uM .713uM View
adrenergic receptor, alpha 2b CISAPRIDE Adrenergic alpha2C 85% .78uM .113uM View
adrenergic receptor, alpha 2c (Non-specific probe) CISAPRIDE Adrenergic alpha2C 85% .78uM .113uM View
5-hydroxytryptamine (serotonin) receptor 2C ATROPINE Serotonin 5-HT2C 85% 1.012uM .53uM View
Sigma-2 Receptor CLEMASTINE Sigma2 85% .728uM .448uM View
adrenergic receptor, alpha 2a CLOZAPINE Imidazoline I2, Central 85% .384uM .256uM View
adrenergic receptor, alpha 2c (Non-specific probe) CLOZAPINE Imidazoline I2, Central 85% .384uM .256uM View
Protein-tyrosine kinase, Fyn S(-)-CARBIDOPA Protein Tyrosine Kinase, Fyn 85% 3.731uM NoneNone View
opioid receptor, sigma 1 MOSAPRIDE Sigma1 85% .3056uM .1284uM View
dopamine receptor D3 MEPAZINE Dopamine D3 85% 2.006uM .681uM View
solute carrier family 6 (neurotransmitter transporter, serotonin), member 4 2-ACETYLAMINOFLUORENE Serotonin Transporter 85% 6.053uM 3.216uM View
Cytochrome P450, subfamily IIC (mephenytoin 4-hydroxylase) 1-(2-FLUOROBENZOYL)-4-(PHENYLMETHYL)-PIPERIDINE CYP450-2C9 Inhibition 85% 2uM NoneNone View
cytochrome P450, family 2, subfamily C, polypeptide 9 1-(2-FLUOROBENZOYL)-4-(PHENYLMETHYL)-PIPERIDINE CYP450-2C9 Inhibition 85% 2uM NoneNone View
sodium channel, voltage-gated, type IV, alpha MEPAZINE Sodium Channel, Site 2 85% 2.521uM 2.3uM View
sodium channel, voltage-gated, type III, alpha MEPAZINE Sodium Channel, Site 2 85% 2.521uM 2.3uM View
sodium channel, voltage-gated, type II, beta MEPAZINE Sodium Channel, Site 2 85% 2.521uM 2.3uM View
sodium channel, voltage-gated, type II, alpha 2 MEPAZINE Sodium Channel, Site 2 85% 2.521uM 2.3uM View
sodium channel, voltage-gated, type I, beta MEPAZINE Sodium Channel, Site 2 85% 2.521uM 2.3uM View
sodium channel, voltage-gated, type I, alpha PUROMYCIN Sodium Channel, Site 2 12% NoneNone NoneNone View
sodium channel, voltage-gated, type I, alpha MEPAZINE Sodium Channel, Site 2 85% 2.521uM 2.3uM View
sodium channel, voltage-gated, type IV, beta MEPAZINE Sodium Channel, Site 2 85% 2.521uM 2.3uM View
sodium channel associated protein 1 MEPAZINE Sodium Channel, Site 2 85% 2.521uM 2.3uM View
sodium channel associated protein 2 MEPAZINE Sodium Channel, Site 2 85% 2.521uM 2.3uM View
sodium channel, voltage-gated, type III, beta MEPAZINE Sodium Channel, Site 2 85% 2.521uM 2.3uM View
sodium channel, voltage-gated, type I, alpha MEPAZINE Sodium Channel, Site 2 85% 2.521uM 2.3uM View
sodium channel, voltage-gated, type IX, alpha MEPAZINE Sodium Channel, Site 2 85% 2.521uM 2.3uM View
sodium channel, voltage-gated, type VII, alpha MEPAZINE Sodium Channel, Site 2 85% 2.521uM 2.3uM View
sodium channel, nonvoltage-gated 1 alpha PAROXETINE Sodium Channel, Site 2 85% 2.69uM 2.454uM View
sodium channel, voltage-gated, type X, alpha PAROXETINE Sodium Channel, Site 2 85% 2.69uM 2.454uM View
sodium channel, voltage-gated, type IX, alpha PAROXETINE Sodium Channel, Site 2 85% 2.69uM 2.454uM View
sodium channel, voltage gated, type VIII, alpha PAROXETINE Sodium Channel, Site 2 85% 2.69uM 2.454uM View
sodium channel, voltage-gated, type VII, alpha PAROXETINE Sodium Channel, Site 2 85% 2.69uM 2.454uM View
sodium channel, voltage-gated, type V, alpha (long QT syndrome 3) PAROXETINE Sodium Channel, Site 2 85% 2.69uM 2.454uM View
sodium channel, voltage-gated, type IV, beta PAROXETINE Sodium Channel, Site 2 85% 2.69uM 2.454uM View
sodium channel, voltage-gated, type IV, alpha PAROXETINE Sodium Channel, Site 2 85% 2.69uM 2.454uM View
sodium channel, voltage-gated, type III, alpha PAROXETINE Sodium Channel, Site 2 85% 2.69uM 2.454uM View
sodium channel, voltage-gated, type II, beta PAROXETINE Sodium Channel, Site 2 85% 2.69uM 2.454uM View
sodium channel, voltage-gated, type II, alpha 2 PAROXETINE Sodium Channel, Site 2 85% 2.69uM 2.454uM View
sodium channel, voltage-gated, type I, beta PAROXETINE Sodium Channel, Site 2 85% 2.69uM 2.454uM View
sodium channel, voltage-gated, type I, alpha PAROXETINE Sodium Channel, Site 2 85% 2.69uM 2.454uM View
sodium channel, voltage-gated, type IV, beta PAROXETINE Sodium Channel, Site 2 85% 2.69uM 2.454uM View
sodium channel associated protein 1 PAROXETINE Sodium Channel, Site 2 85% 2.69uM 2.454uM View
sodium channel associated protein 2 PAROXETINE Sodium Channel, Site 2 85% 2.69uM 2.454uM View
sodium channel, voltage-gated, type III, beta PAROXETINE Sodium Channel, Site 2 85% 2.69uM 2.454uM View
sodium channel, voltage-gated, type I, alpha PAROXETINE Sodium Channel, Site 2 85% 2.69uM 2.454uM View
sodium channel, voltage-gated, type IX, alpha PAROXETINE Sodium Channel, Site 2 85% 2.69uM 2.454uM View
Sigma-2 Receptor PROCHLORPERAZINE Sigma2 85% .676uM .416uM View